Pramipexole/rasagiline

Drug Profile

Pramipexole/rasagiline

Alternative Names: P2B-001; Rasagaline/pramipexole

Latest Information Update: 06 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharma Two B
  • Class Antiparkinsonians; Benzothiazoles; Indans; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists; Dopamine D4 receptor agonists; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Parkinson's disease

Most Recent Events

  • 06 Mar 2017 Pramipexole/rasagiline is still under phase IIb/III development stage for Parkinson's disease (Early-stage disease) in USA and Israel (PO)
  • 07 Jul 2016 Pharma Two B completes a phase IIb trial in Parkinson's disease (early-stage disease) in USA and Israel before July 2016 (Pharma Two B pipeline, July 2016)
  • 30 Jun 2015 Pramipexole/rasagiline is available for licensing as of 30 Jun 2015. http://www.pharma2b.com/en/Default.aspx#
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top